A randomised double-blind trial comparing Gutt. prednisolone 0.3% Gutt. flurbiprofen 0.03% and Gutt. saline 0.5% in the treatment of episcleritis.
included in the trial. Rapid spontaneous improvement in symptoms and signs was noted in the majority of cases.
There was no significant difference between the cure-rates of patients treated with fturbiprofen and placebo over a 3-week trial period. The proportion of patients treated with prednisolone 0.3% who were cured was significantly higher than in either of the other groups after 3 weeks.
Episcleritis is generally considered to be a benign condition. Although patients com plain of discomfort and of the appearance of their inflamed eye, the problem is recognised as self-limiting. However, it represents one end of the spectrum of ocular inflammatory disease, with necrotising scleral disease at the other. Previous authors! have suggested that resolution of the inflammatory episode can be hastened by topical treatment with beta methasone or, to a lesser extent by non-steroi dal anti-inflammatory drugs such as Tanderil.
Currently, topical steroids are the mainstay of the treatment of episcleritis; however they are known to give rise to an inflammatory rebound phenomenon as well as to other well documented ocular side-effects such as reac tivation of Herpes Simplex Keratitis.
Flurbiprofen is one of the few non-steroidal anti-inflammatory drugs which has been found to be effective in the management of scleral inflammatory disease.2 However, like other drugs in this class, oral administration is The proportion of patients free of symp toms and signs was calculated for each group at weeks 1, 2 and 3. This is illustrated in Gutt prednisolone 0.3% is significantly bet ter than gutt placebo and gutt flurbiprofen at curing pain (significant by two weeks p=0.04) and episcleral injection (significant at three weeks p=0.015, p=0.007).
Discussion
The results of this double-blind trial show that gutt. flurbiprofen is no better than gutt. pla cebo at treating episcleritis.
This study confirms that in the majority of • WEEK 0
Figs. 1 and 2. Average scores for pain and episcleral injection at weeks 0, 1, 2 and 3 for each of the treatment groups. 
Conclusions
This study confirms episcleritis to be a con dition which is usually benign and self-lim iting. However, the course of the inflammatory process can be variable and pro gression to scleritis was observed in six of 77 eyes.
Treatment with topical prednisolone has been shown to be superior to either topical flurbiprofen or placebo in achieving reso lution of episcleral inflammation. Although no complications related to the use of topical prednisolone were encountered in this study,
we would recommend that its use should be restricted to inflammation which has failed to improve spontaneously after one week.
